Author

John Eikelboom

Unknown affiliation - Cited by 1,90,813

Biography

Dr John Eikelboom is an associate professor in the Department of Medicine at McMaster University in Hamilton, Ontario. After earning his MBBS degree at the University of Western Australia Medical School, Australia, he completed training in Internal Medicine and Haematology at Royal Perth Hospital, Australia and trained in Epidemiology and Thrombosis Medicine at McMaster University. He holds a Canada Research Chair in Cardiovascular Medicine from the Canadian Institutes for Health Research. Dr. Eikelboom’s current research focuses on variable response to antiplatelet therapy, antithrombotic therapy in atrial fibrillation, and mechanisms and prognosis of bleeding.
Title
Cited by
Year
A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse …
SV Rao, B Kirsch, DL Bhatt, A Budaj, R Coppolecchia, J Eikelboom, ...Circulation 146 (16), 1196-1206, 2022202
43
2022
Factor XI inhibitors: cardiovascular perspectives
R De Caterina, D Prisco, JW EikelboomEuropean heart journal 44 (4), 280-292, 2023202
21
2023
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
JW Eikelboom, SS Jolly, EP Belley-Cote, RP Whitlock, S Rangarajan, ...The Lancet Respiratory Medicine 10 (), 1169-1177, 2022202
12
2022
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
JW Eikelboom, SS Jolly, EP Belley-Cote, RP Whitlock, S Rangarajan, ...The Lancet Respiratory Medicine (12), 1160-1168, 2022202
10
2022
Conduit selection and early graft failure in coronary artery bypass surgery: a post hoc analysis of the Cardiovascular Outcomes for People Using Anticoagulation Strategies …
M Alboom, A Browne, T Sheth, Z Zheng, F Dagenais, N Noiseux, M Brtko, ...The Journal of Thoracic and Cardiovascular Surgery 165 (3), 80-89. e1, 2023202
10
2023
Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week
R De Caterina, S Agewall, F Andreotti, DJ Angiolillo, DL Bhatt, RA Byrne, ...European Heart Journal 43 (37), 3512-3527, 2022202
9
2022
Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in …
M Marcucci, TW Painter, D Conen, K Leslie, VV Lomivorotov, D Sessler, ...Trials 23 (1), 1-12, 2022202
8
2022
Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
Z Hijazi, AP Benz, J Lindbäck, JH Alexander, SJ Connolly, JW Eikelboom, ...European heart journal 44 (3), 20-21, 2023202
8
2023
Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials
AP Benz, I Johansson, WJM Dewilde, RD Lopes, R Mehran, S Sartori, ...European Heart Journal-Cardiovascular Pharmacotherapy 8 (7), 48-59, 2022202
6
2022
Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial
M Hori, J Zhu, Y Liang, DL Bhatt, J Bosch, SJ Connolly, KAA Fox, ...European Heart Journal 43 (37), 3542-3552, 2022202
6
2022
Long-term treatment with the combination of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: outcomes during the open label extension of …
JW Eikelboom, J Bosch, SJ Connolly, J Tyrwitt, KAA Fox, E Muehlhofer, ...European Heart Journal-Cardiovascular Pharmacotherapy 8 (8), 78-795, 2022202
6
2022
The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose Colchicine 2 (LoDoCo2 …
A van Broekhoven, N Mohammadnia, MJM Silvis, J Los, ATL Fiolet, ...Clinical drug investigation 42 (11), 977-985, 2022202
3
2022
Comparison of investigator-reported vs centrally adjudicated major adverse cardiac events: a secondary analysis of the COMPASS trial
P Gaba, DL Bhatt, GR Dagenais, J Bosch, AP Maggioni, P Widimsky, ...JAMA network open 5 (11), e224201-e224201, 2022202
3
2022
Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial
Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine trialTSJ Opstal, SM Nidorf, ATL Fiolet, JW Eikelboom, A Mosterd, WA Bax, ...International Journal of Cardiology 37, 1-5, 030
2
2023
Final study report of Andexanet Alfa for major bleeding with factor xa inhibitors
TJ Milling Jr, S Middeldorp, L Xu, B Koch, A Demchuk, JW Eikelboom, ...Circulation 147 (13), 106-1038, 030
2
2023
Health status and cognitive function for risk stratification in chronic coronary and peripheral artery disease
KG Smolderen, C Mena-Hurtado, JW Eikelboom, J Bosch, F Xie, ...European Journal of Preventive Cardiology 30 (7), 535-545, 030
2
2023
Clinical studies with anticoagulants that have changed clinical practice
J Hirsh, TAC de Vries, JW Eikelboom, V Bhagirath, NC ChanSeminars in Thrombosis and Hemostasis 49 (03), 4-54, 030
2
2023
What Is the Future of Factor XI Inhibitors?
JI Weitz, JW EikelboomCirculation 146 (5), 1899-190, 0
2
2022
Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation
AP Benz, SH Hohnloser, JW Eikelboom, AP Carnicelli, RP Giugliano, ...European Heart Journal 44 (0), 1807-1814, 030
2
2023
Validating fatty acid binding protein 3 as a diagnostic and prognostic biomarker for peripheral arterial disease: A three-year prospective follow-up study
A Zamzam, MH Syed, OD Rotstein, J Eikelboom, DJ Klein, KK Singh, ...EClinicalMedicine 55, 2023202
1
2023

Referred From: https://scholar.google.ca/citations?user=ro7dIZQAAAAJ&hl=en

Cited by
Citations 190813
h-index 135
i10-index 563
Recommended Journals
Open Access Journals